Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2797]

ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage RET fusion-positive NSCLC

ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage...

ASCO 2026: Ivonescimab may improve overall survival in patients with advanced squamous non-small cell lung cancer

ASCO 2026: Ivonescimab may improve overall survival in patients with advanced squamous non-small cell lung cancer

ASCO 2026: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

ASCO 2026: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

KRAS degradation induces rapid lung cancer regression in preclinical mouse models

KRAS degradation induces rapid lung cancer regression in preclinical mouse models

ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers

ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers

Institute researchers identify new drug targets for hard-to-treat cancers

Institute researchers identify new drug targets for hard-to-treat cancers

Nervous system helps lung cancer evade the immune system

Nervous system helps lung cancer evade the immune system

Comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A simple X-ray measure linked to survival in lung cancer surgery patients

A simple X-ray measure linked to survival in lung cancer surgery patients

How immune-related adverse events differ in elderly gastrointestinal vs. lung cancer patients

How immune-related adverse events differ in elderly gastrointestinal vs. lung cancer patients

More from ecancer